US6531315B1
(en)
|
1998-03-18 |
2003-03-11 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
US6696247B2
(en)
|
1998-03-18 |
2004-02-24 |
Corixa Corporation |
Compounds and methods for therapy and diagnosis of lung cancer
|
US6960570B2
(en)
|
1998-03-18 |
2005-11-01 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
US6518256B1
(en)
|
1998-03-18 |
2003-02-11 |
Corixa Corporation |
Compounds and methods for therapy and diagnosis of lung cancer
|
US6426072B1
(en)
|
2000-08-02 |
2002-07-30 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
US6706262B1
(en)
|
1998-03-18 |
2004-03-16 |
Corixa Corporation |
Compounds and methods for therapy and diagnosis of lung cancer
|
US7579160B2
(en)
|
1998-03-18 |
2009-08-25 |
Corixa Corporation |
Methods for the detection of cervical cancer
|
US6660838B1
(en)
|
1998-03-18 |
2003-12-09 |
Corixa Corporation |
Compounds and methods for therapy and diagnosis of lung cancer
|
US6312695B1
(en)
|
1998-03-18 |
2001-11-06 |
Corixa Corporation |
Compounds and methods for therapy of lung cancer
|
US7049063B2
(en)
|
1998-03-18 |
2006-05-23 |
Corixa Corporation |
Methods for diagnosis of lung cancer
|
US7258860B2
(en)
|
1998-03-18 |
2007-08-21 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
US6482597B1
(en)
|
1999-12-17 |
2002-11-19 |
Corixa Corporation |
Compounds and methods for therapy and diagnosis of lung cancer
|
US6737514B1
(en)
|
1998-12-22 |
2004-05-18 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
US6821518B1
(en)
|
1998-03-18 |
2004-11-23 |
Corixa Corporation |
Compounds and methods for therapy and diagnosis of lung cancer
|
CA2349593A1
(fr)
*
|
1998-11-05 |
2000-05-11 |
The Regents Of The University Of Michigan |
Proteines s100 et auto-anticorps comme marqueurs seriques pour le cancer
|
AU2004201392B2
(en)
*
|
1998-11-05 |
2007-06-14 |
The Regents Of The University Of Michigan |
S100 proteins and autoantibodies as serum markers for cancer
|
ES2308976T3
(es)
*
|
1999-04-02 |
2008-12-16 |
Corixa Corporation |
Compuestos y metodos para la terapia y el diagnostico del cancer de pulmon.
|
AU2002246668A1
(en)
*
|
2000-11-02 |
2002-07-30 |
Molecular Discoveries, L.L.C. |
Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (sclc)
|
EP1373896A2
(fr)
*
|
2001-03-12 |
2004-01-02 |
MonoGen, Inc. |
Detection et differenciation d'etats pathologiques par echantillons cellulaires
|
CA2489860C
(fr)
*
|
2002-07-05 |
2015-02-10 |
Universite Laval |
Utilisation d'un anticorps dirige contre s100a8 ou a1009 en tant qu'inhibiteur de facteur chimiotactique destine a moduler des reactions inflammatoires
|
AU2002951153A0
(en)
*
|
2002-09-02 |
2002-09-19 |
Proteome Systems Intellectual Property Pty Ltd |
An electrophoresis gel having improved swelling properties
|
CA2565872C
(fr)
*
|
2004-05-11 |
2016-06-21 |
Abgenomics Corporation |
Epitopes induisant la mort des lymphocytes t
|
CA2573596A1
(fr)
*
|
2004-07-13 |
2006-01-19 |
Universite Laval |
Inhibiteurs de la proteine s100 utilises pour le traitement la leucemie
|
NZ553386A
(en)
*
|
2004-07-23 |
2010-05-28 |
Aspenbio Pharma Inc |
Methods and devices for diagnosis of appendicitis
|
US7659087B2
(en)
*
|
2004-07-23 |
2010-02-09 |
Aspenbio Pharma, Inc. |
Methods and devices for diagnosis of appendicitis
|
ES2333182T3
(es)
|
2005-05-18 |
2010-02-17 |
Array Biopharma, Inc. |
Derivados de 4-(fenilamino)-6-oxo-1,6-dihidropiridazina-3-carboxamida como inhibidores de mek para el tratamiento de enfermedades hiperproliferativas.
|
KR100732298B1
(ko)
*
|
2005-11-24 |
2007-06-25 |
이화여자대학교 산학협력단 |
유비키틴 c-말단 가수분해제-l1을 이용한 암전이 진단용조성물
|
TW200813091A
(en)
|
2006-04-10 |
2008-03-16 |
Amgen Fremont Inc |
Targeted binding agents directed to uPAR and uses thereof
|
CL2007002225A1
(es)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
|
SI2057156T1
(sl)
*
|
2006-08-23 |
2017-06-30 |
Kudos Pharmaceuticals Limited |
Derivati 2-metilmorfolin pirido-, pirazo- in pirimido-pirimidina kot inhibitorji mTOR
|
US8044056B2
(en)
|
2007-03-20 |
2011-10-25 |
Dainippon Sumitomo Pharma Co., Ltd. |
Adenine compound
|
AR065784A1
(es)
|
2007-03-20 |
2009-07-01 |
Dainippon Sumitomo Pharma Co |
Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas.
|
PL2195645T3
(pl)
*
|
2007-09-11 |
2014-12-31 |
Cancer Prevention & Cure Ltd |
Metoda wspomagająca diagnostykę i terapię astmy i rak płuc
|
AU2008309383B2
(en)
|
2007-10-11 |
2012-04-19 |
Astrazeneca Ab |
Pyrrolo [2, 3 -D] pyrimidin derivatives as protein kinase B inhibitors
|
PE20131210A1
(es)
|
2007-12-19 |
2013-10-31 |
Genentech Inc |
Derivados de 5-anilinoimidazopiridina como inhibidores de mek
|
CA2708176A1
(fr)
|
2007-12-21 |
2009-07-02 |
Genentech, Inc. |
Azaindolizines et procedes d'utilisation
|
CA2735900A1
(fr)
|
2008-09-19 |
2010-03-25 |
Medimmune, Llc |
Anticorps diriges contre dll4 et leurs utilisations
|
US20110053923A1
(en)
|
2008-12-22 |
2011-03-03 |
Astrazeneca |
Chemical compounds 610
|
JP2012513194A
(ja)
|
2008-12-23 |
2012-06-14 |
アストラゼネカ アクチボラグ |
α5β1に向けられた標的結合剤およびその使用
|
EP3100745B1
(fr)
|
2009-02-05 |
2018-04-18 |
Immunogen, Inc. |
Nouveaux dérivés de benzodiazépine
|
CN104535765A
(zh)
|
2009-03-12 |
2015-04-22 |
癌症预防和治疗有限公司 |
鉴定、评估、预防以及治疗肺疾病的方法及试剂盒
|
WO2010103094A1
(fr)
|
2009-03-13 |
2010-09-16 |
Cellzome Limited |
Dérivés de pyrimidine comme inhibiteurs du mtor
|
CA2758614A1
(fr)
|
2009-04-14 |
2010-10-21 |
Cellzome Limited |
Composes de pyrimidine substitues par fluoro en tant qu'inhibiteurs de jak3
|
US8389580B2
(en)
|
2009-06-02 |
2013-03-05 |
Duke University |
Arylcyclopropylamines and methods of use
|
CA2771675A1
(fr)
|
2009-09-11 |
2011-03-17 |
Cellzome Limited |
Composes de pyrimidine ortho-substitues en tant qu'inhibiteurs de jak
|
CN102666545B
(zh)
|
2009-10-20 |
2016-04-06 |
塞尔卓姆有限公司 |
作为jak抑制剂的杂环吡唑并嘧啶类似物
|
EP3279215B1
(fr)
|
2009-11-24 |
2020-02-12 |
MedImmune Limited |
Agents de liaison ciblés contre b7-h1
|
JP2013512859A
(ja)
|
2009-12-03 |
2013-04-18 |
大日本住友製薬株式会社 |
トール様受容体(tlr)を介して作用するイミダゾキノリン
|
EP2521920A4
(fr)
*
|
2010-01-08 |
2013-06-05 |
Univ California |
Marqueurs de protéine pour détection du cancer du poumon et leurs procédés d'utilisation
|
EP2533810B1
(fr)
|
2010-02-10 |
2016-10-12 |
ImmunoGen, Inc. |
Anticorps anti-cd20 et utilisations de ceux-ci
|
ES2535116T3
(es)
|
2010-03-04 |
2015-05-05 |
Cellzome Limited |
Derivados de urea sustituida con morfolino como inhibidores de mtor
|
JP2013525392A
(ja)
|
2010-04-30 |
2013-06-20 |
セルゾーム リミティッド |
Jak阻害剤としてのピラゾール化合物
|
SA111320519B1
(ar)
|
2010-06-11 |
2014-07-02 |
Astrazeneca Ab |
مركبات بيريميدينيل للاستخدام كمثبطات atr
|
WO2012000970A1
(fr)
|
2010-07-01 |
2012-01-05 |
Cellzome Limited |
Triazolopyridines en tant qu'inhibiteurs de tyk2
|
JP2013534233A
(ja)
|
2010-08-20 |
2013-09-02 |
セルゾーム リミティッド |
選択的jak阻害剤としてのヘテロシクリルピラゾロピリミジン類似体
|
CA2815330A1
(fr)
|
2010-11-09 |
2012-05-18 |
Cellzome Limited |
Composes de pyridine et leurs analogues aza en tant qu'inhibiteurs de tyk2
|
MY183977A
(en)
|
2011-02-15 |
2021-03-17 |
Immunogen Inc |
Cytotoxic benzodiazepine derivatives
|
CA2827172C
(fr)
|
2011-02-17 |
2019-02-26 |
Cancer Therapeutics Crc Pty Limited |
Inhibiteurs selectifs de fak
|
JP5937111B2
(ja)
|
2011-02-17 |
2016-06-22 |
カンサー・セラピューティクス・シーアールシー・プロプライエタリー・リミテッドCancer Therapeutics Crc Pty Limited |
Fak阻害剤
|
US20140163023A1
(en)
|
2011-04-04 |
2014-06-12 |
Cellzome Limited |
Dihydropyrrolo pyrimidine derivatives as mtor inhibitors
|
WO2012143320A1
(fr)
|
2011-04-18 |
2012-10-26 |
Cellzome Limited |
Composés (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine comme inhibiteurs de la jak3
|
AU2012288892B2
(en)
|
2011-07-28 |
2016-04-21 |
Cellzome Limited |
Heterocyclyl pyrimidine analogues as JAK inhibitors
|
WO2013017479A1
(fr)
|
2011-07-29 |
2013-02-07 |
Cellzome Limited |
Dérivés de pyrazolo[4,3-c]pyridine en tant qu'inhibiteurs de jak
|
WO2013017480A1
(fr)
|
2011-07-29 |
2013-02-07 |
Cellzome Limited |
Dérivés de pyrazolo[4,3-c]pyridine en tant qu'inhibiteurs de jak
|
EP2760863A1
(fr)
|
2011-09-20 |
2014-08-06 |
Cellzome Limited |
Dérivés de pyrazolo[4,3-c]pyridine comme inhibiteurs de kinases
|
AU2012311458B2
(en)
|
2011-09-21 |
2016-02-04 |
Cellzome Limited |
Morpholino substituted urea or carbamate derivatives as mTOR inhibitors
|
US9242993B2
(en)
|
2011-10-07 |
2016-01-26 |
Cellzome Limited |
Morpholino substituted bicyclic pyrimidine urea or carbamate derivatives as mTOR inhibitors
|
US20130178520A1
(en)
|
2011-12-23 |
2013-07-11 |
Duke University |
Methods of treatment using arylcyclopropylamine compounds
|
CN104169272A
(zh)
|
2011-12-23 |
2014-11-26 |
赛尔佐姆有限公司 |
作为激酶抑制剂的嘧啶-2,4-二胺衍生物
|
EP3505534A1
(fr)
|
2012-06-08 |
2019-07-03 |
Sutro Biopharma, Inc. |
Anticorps comprenant des résidus d'acides aminés non endogènes spécifiques d'un site, leurs procédés de préparation et leurs procédés d'utilisation
|
ES2611788T3
(es)
|
2012-06-26 |
2017-05-10 |
Sutro Biopharma, Inc. |
Proteínas de Fc modificadas que comprenden residuos de aminoácidos no naturales específicos del sitio, conjugados de las mismas, métodos para su preparación y métodos para su uso
|
CA2882158A1
(fr)
|
2012-08-17 |
2014-02-20 |
Cancer Therapeutics Crc Pty Limited |
Inhibiteurs de vegfr3
|
WO2014031566A1
(fr)
|
2012-08-22 |
2014-02-27 |
Immunogen, Inc. |
Dérivés de benzodiazépine cytotoxique
|
BR112015004022B1
(pt)
|
2012-08-31 |
2023-04-25 |
Sutro Biopharma, Inc |
Aminoácidos modificados compreendendo um grupo azido
|
WO2014041349A1
(fr)
|
2012-09-12 |
2014-03-20 |
Cancer Therapeutics Crc Pty Ltd |
Pyrimidines ou pyridazines tétrahydropyran-4-yléthylamino- ou tétrahydropyranyl-4-éthyloxy utiles comme inhibiteurs de l'isoprényl-cystéine-carboxy-méthyl-transférase
|
WO2014045101A1
(fr)
|
2012-09-21 |
2014-03-27 |
Cellzome Gmbh |
Dérivés de tétrazolo quinoxaline utilisés comme inhibiteurs de la tankyrase
|
WO2014134486A2
(fr)
|
2013-02-28 |
2014-09-04 |
Immunogen, Inc. |
Conjugués comprenant des agents de liaison cellulaire (cba) et des agents cytotoxiques
|
JP6494533B2
(ja)
|
2013-02-28 |
2019-04-03 |
イミュノジェン・インコーポレーテッド |
細胞結合剤及び細胞毒性剤としてのマイタンシノイドを含む複合体
|
AR095443A1
(es)
|
2013-03-15 |
2015-10-14 |
Fundación Centro Nac De Investig Oncológicas Carlos Iii |
Heterociclos condensados con acción sobre atr
|
WO2014194030A2
(fr)
|
2013-05-31 |
2014-12-04 |
Immunogen, Inc. |
Conjugués comprenant des agents de liaison cellulaire et des agents cytotoxiques
|
US9764039B2
(en)
|
2013-07-10 |
2017-09-19 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
WO2015054658A1
(fr)
|
2013-10-11 |
2015-04-16 |
Sutro Biopharma, Inc. |
Acides aminés modifiés comprenant des groupes fonctionnels de tétrazine, procédés de préparation et procédés d'utilisation associés
|
GB201510019D0
(en)
|
2015-06-09 |
2015-07-22 |
Cancer Therapeutics Crc Pty Ltd |
Compounds
|
SG11201806419RA
(en)
|
2016-01-27 |
2018-08-30 |
Sutro Biopharma Inc |
Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
|
CN107459519A
(zh)
|
2016-06-06 |
2017-12-12 |
上海艾力斯医药科技有限公司 |
稠合嘧啶哌啶环衍生物及其制备方法和应用
|
AU2017321973A1
(en)
|
2016-09-02 |
2019-03-07 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of treating B cell disorders
|
US10287253B2
(en)
|
2016-12-05 |
2019-05-14 |
Apros Therapeutics, Inc. |
Substituted pyrimidines containing acidic groups as TLR7 modulators
|
US10786502B2
(en)
|
2016-12-05 |
2020-09-29 |
Apros Therapeutics, Inc. |
Substituted pyrimidines containing acidic groups as TLR7 modulators
|
CN110709936A
(zh)
|
2017-04-04 |
2020-01-17 |
肺癌蛋白质组学有限责任公司 |
用于早期肺癌预后的基于血浆的蛋白质概况分析
|
WO2019023316A1
(fr)
|
2017-07-26 |
2019-01-31 |
Sutro Biopharma, Inc. |
Méthodes d'utilisation d'anticorps anti-cd74 et de conjugués d'anticorps dans le traitement d'un lymphome à cellules t
|
US20200353076A1
(en)
|
2017-09-18 |
2020-11-12 |
Sutro Biopharma, Inc. |
Anti-folate receptor alpha antibody conjugates and their uses
|
NL2019801B1
(en)
|
2017-10-25 |
2019-05-02 |
Univ Leiden |
Delivery vectors
|
CN112513031A
(zh)
|
2018-06-04 |
2021-03-16 |
阿普罗斯治疗公司 |
可用于治疗与tlr7调节相关的疾病的含酸性基团的嘧啶化合物
|
GB201810092D0
(en)
|
2018-06-20 |
2018-08-08 |
Ctxt Pty Ltd |
Compounds
|
GB201810581D0
(en)
|
2018-06-28 |
2018-08-15 |
Ctxt Pty Ltd |
Compounds
|
US20220047716A1
(en)
|
2018-09-17 |
2022-02-17 |
Sutro Biopharma, Inc. |
Combination therapies with anti-folate receptor antibody conjugates
|
EP3962951A1
(fr)
|
2019-05-03 |
2022-03-09 |
Sutro Biopharma, Inc. |
Conjugués d'anticorps anti-bcma
|
CA3152674A1
(fr)
|
2019-08-31 |
2021-03-04 |
Etern Biopharma (Shanghai) Co., Ltd. |
Derives de pyrazole pour l'inhibiteur des fgfr et methode de preparation connexe
|
WO2021178597A1
(fr)
|
2020-03-03 |
2021-09-10 |
Sutro Biopharma, Inc. |
Anticorps comprenant des étiquettes de glutamine spécifiques à un site, leurs procédés de préparation et d'utilisation
|
TW202408589A
(zh)
|
2022-06-30 |
2024-03-01 |
美商舒卓生物製藥公司 |
抗ror1抗體及抗體結合物、包含抗ror1抗體或抗體結合物之組合物,及製造及使用抗ror1抗體及抗體結合物之方法
|